AL (immunoglobulin light chain) amyloidosis is a rare disease that often results in progressive organ dysfunction, organ failure and eventual death. Clonal plasma cells in the bone marrow secrete free ...

Please provide your email address to receive an email when new articles are posted on . ALXN2220, a novel investigational depleter monoclonal antibody, was granted fast track designation by the FDA.

Prothena is laying off almost two-thirds of its workforce as the Irish biotech navigates the fallout from giving up on its failed amyloidosis drug. In May, the company announced the failure of the ...

This rare condition can’t be cured, but its symptoms can be treated. Take this assessment to learn what more you can do to manage the condition. Before you were diagnosed with transthyretin ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. The Big ...

Top line results from a phase 3 trial of vutrisiran (Amvuttra), a new drug from Alnylam for the treatment of transthyretin-mediated amyloidosis with cardiomyopathy, are positive, according to the ...

In their study published in the Mayo Clinic Proceedings, UAB researchers collaborated with researchers from Weill Cornell Medicine and Columbia University to show that carpal tunnel syndrome preceded ...

MSK cellular therapist Dr. Heather Landau led a phase 1 clinical trial showing CAR T cell therapy is effective against relapsed or resistant AL amyloidosis. “I’ve seen very sick patients have an ...

The European Medicines Agency (EMA) recommended in its April meetings approval of marketing authorizations for two orphan medicines: Alyftrek for the treatment of cystic fibrosis and Attrogy for the ...

One of the most serious complications of rheumatologic and autoimmune diseases can be prevented with biologic drugs, a single-center chart review suggested, and some such products may be more ...